AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Protalix BioTherapeutics, Inc. Common Stock
XASE · usd
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG001SBVMW4
2.55▼ 0.02 (-0.78%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
2.57
Day's Range
2.50 – 2.56
52-Week Range
1.65 – 3.19
Volume
383.9K
Avg Volume
843.1K
Share Statistics
Shares Outstanding
Employees
226
Exchange
XASE
Listed
1996-01-02
Share count as of August 1, 2026

Protalix BioTherapeutics, Inc. Common Stock (PLX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Protalix BioTherapeutics, Inc. Common Stock (PLX)
What is Protalix BioTherapeutics, Inc. Common Stock's Market Cap?
Protalix BioTherapeutics, Inc. Common Stock's Market Cap is $205.5M, based on as-reported figures from SEC (XBRL) filings.
What is Protalix BioTherapeutics, Inc. Common Stock's Enterprise Value?
Protalix BioTherapeutics, Inc. Common Stock's Enterprise Value is $178.0M, based on as-reported figures from SEC (XBRL) filings.
What is Protalix BioTherapeutics, Inc. Common Stock's Trailing P/E?
Protalix BioTherapeutics, Inc. Common Stock's Trailing P/E is 10.8×, based on as-reported figures from SEC (XBRL) filings.
What is Protalix BioTherapeutics, Inc. Common Stock's Price / Sales?
Protalix BioTherapeutics, Inc. Common Stock's Price / Sales is 2.5×, based on as-reported figures from SEC (XBRL) filings.
What is Protalix BioTherapeutics, Inc. Common Stock's EV / Revenue?
Protalix BioTherapeutics, Inc. Common Stock's EV / Revenue is 2.2×, based on as-reported figures from SEC (XBRL) filings.
What is Protalix BioTherapeutics, Inc. Common Stock's EV / EBITDA?
Protalix BioTherapeutics, Inc. Common Stock's EV / EBITDA is 7.2×, based on as-reported figures from SEC (XBRL) filings.
What is Protalix BioTherapeutics, Inc. Common Stock's Revenue (TTM)?
Protalix BioTherapeutics, Inc. Common Stock's Revenue (TTM) is $80.6M, based on as-reported figures from SEC (XBRL) filings.
What is Protalix BioTherapeutics, Inc. Common Stock's Net Income (TTM)?
Protalix BioTherapeutics, Inc. Common Stock's Net Income (TTM) is $18.9M, based on as-reported figures from SEC (XBRL) filings.
What is Protalix BioTherapeutics, Inc. Common Stock's EBITDA?
Protalix BioTherapeutics, Inc. Common Stock's EBITDA is $24.9M, based on as-reported figures from SEC (XBRL) filings.
What is Protalix BioTherapeutics, Inc. Common Stock's Diluted EPS (TTM)?
Protalix BioTherapeutics, Inc. Common Stock's Diluted EPS (TTM) is 0.24, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · PLXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
TOTAL REVENUE
YoY growth+27.1%+233.7%-49.9%-0.6%
COST OF REVENUES
RESEARCH AND DEVELOPMENT EXPENSES, NET
SELLING, GENERAL, AND ADMINISTRATIVE EXPENSES
OPERATING INCOME (LOSS)
% of revenue23.5%62.7%-51.1%11.9%
FINANCIAL EXPENSES
FINANCIAL INCOME
FINANCIAL INCOME (EXPENSES), NET
INCOME (LOSS) BEFORE TAXES ON INCOME
TAXES ON INCOME
NET INCOME (LOSS)
% of revenue19.0%54.3%-60.3%13.2%
EARNINGS (LOSS) PER SHARE OF COMMON STOCK - BASIC (in dollars per share)
EARNINGS (LOSS) PER SHARE OF COMMON STOCK - DILUTED (in dollars per share)